

Going beyond Commitment



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 th JUNE ' 2018

PART - I					Rs. In Lakhs
Sl. No.	PARTICULARS	For the Quarter Ended			For the year Ended
		30/06/2018	31/03/2018	30/06/2017	31/03/2018
		Un Audited	Audited	Un-Audited	Audited
1	Revenue from operations				
	(a) Net sales/income from operations	18,487.99	20,829.49	13,744.90	61,258.22
	(b) Other operating income	678.23	542.84	357.00	1,267.62
	Total income from operations (net)	19,166.22	21,372.33	14,101.90	62,525.84
2	Other Income	812.77	922.60	562.29	2,327.07
	Total income (1+2)	19,978.99	22,294.93	14,664.19	64,852.91
3	Expenses				
	a) Cost of materials consumed	3,859.30	4,483.78	3,683.53	17,490.30
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,595.82	1,482.12	(227.17)	(2,120.13)
	d) Employee benefits expense	1,714.82	1,557.92	1,566.22	5,873.50
	e) Finance costs	106.79	125.36	127.01	461.11
	f) Depreciation and amortisation expense	550.81	536.14	519.20	2,130.99
	g) Manufacturing Exps	2,285.50	2,150.75	2,190.37	8,821.54
	h) R & D Exps	1,598.87	1,691.51	1,601.19	5,846.66
	i) Other Expenses	1,288.81	882.03	759.06	3,322.37
	Total expenses	14,000.72	12,909.61	10,219.41	41,826.34
4	Profit / (Loss) before exceptional items & Tax (1+2-3)	5,978.27	9,385.32	4,444.78	23,026.57
5	Exceptional Items	-	-	-	-
6	Profit / (Loss) before Tax (4-5)	5,978.27	9,385.32	4,444.78	23,026.57
7	Tax Expenses				
	a) Current tax	1,249.14	2,016.93	1,132.77	4,756.49
	b) Deferred tax	844.92	1,117.28	354.94	2,427.35
8	Net Profit/ (Loss) for the period/year(6-7)	3,884.21	6,251.11	2,957.07	15,842.73
9	Other Comprehensive Income				
9.a	(i) Items that will not be reclassified to profit or loss	(10.58)	(31.15)	(3.73)	(42.33)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.66	10.78	1.29	14.65
9.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(6.92)	(20.37)	(2.44)	(27.68)
10	Total Comprehensive Income for the period (8+9)	3,877.29	6,230.74	2,954.63	15,815.05
11	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
12	Other Equity				85,397.16
13	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	3.05	4.90	2.32	12.43
	b) Diluted	3.05	4.90	2.32	12.43
		(not annualised)	(not annualised)	(not annualised)	

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES

Rs in Lakhs

PARTICULARS	For the Quarter Ended			For the year Ended
	30/06/2018	31/03/2018	30/06/2017	31/03/2018
	Un Audited	Audited	Un-Audited	Audited
1 SEGMENT REVENUE :-				
a) Manufaturing (CRAMS)	18,024.22	20,636.53	13,330.76	59,687.64
b) Services (DDDSS)	1,142.00	735.80	771.14	2,838.20
c) Research & Development	-	-	-	-
TOTAL	19,166.22	21,372.33	14,101.90	62,525.84
Less Inter segment Revenue	-	-	-	-
Net Sales from Operations	19,166.22	21,372.33	14,101.90	62,525.84
2 SEGMENT RESULTS :-				
Profit/(Loss) before tax and interest:				
a) Manufaturing (CRAMS)	7,086.74	10,492.63	5,782.86	28,031.87
b) Services (DDDSS)	761.15	436.40	405.25	1,428.77
c) Research & Development	(1,598.88)	(1,691.51)	(1,601.18)	(5,846.66)
TOTAL	6,249.01	9,237.52	4,586.93	23,613.98
Less: i) Finance costs	35.97	47.88	87.11	281.59
ii) Other Un-allocable expenditure/(Income), net	234.77	(195.65)	55.04	305.82
Total Profit Before Tax	5,978.27	9,385.29	4,444.78	23,026.57
3 SEGMENT ASSETS :				
a) Manufaturing (CRAMS)	48,587.81	52,557.03	47,190.09	52,557.03
b) Services (DDDSS)	4,339.17	4,061.14	3,511.49	4,061.14
c) Research & Development	2,784.33	3,031.96	2,540.08	3,031.96
d) Un allocated	50,187.02	41,234.30	37,517.52	41,234.30
TOTAL	105,898.33	100,884.43	90,759.18	100,884.43
SEGMENT LIABILITIES :				
a) Manufaturing (CRAMS)	9,053.42	8,594.07	8,830.42	8,594.07
b) Services (DDDSS)	315.25	382.64	428.06	382.64
c) Research & Development	1,323.46	1,587.28	1,873.25	1,587.28
d) Un allocated	867.09	714.79	722.22	714.79
TOTAL	11,559.22	11,278.78	11,853.95	11,278.78

Notes: 1) The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the period presented been prepared in accordance with the recognition and measurement principles of Ind AS 34.

2) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th Aug 2018 and the same reviewed by the Statutory Auditors.

3) Excise duty on sales was included under Revenue from operations and disclosed separately under expenses upto all reporting periods ending June 2017. Post implementation of GST Act wef 1st July 2017 the revenue from operations is reported for the period ended June 2018 is net of GST and hence to that extent not comparable.

4) Effective from 1st April 2018, the company has adopted Ind AS-115, "Revenue from contract with customers". The application of Ind AS-115 does not have any significant impact on recognition and measurement of revenue from operations and other related items in the financial results of the company.

5) The figures for Qtr ended 31 Mar 2018 are the balancing figures between audited figures in respect of the full financial year ended 31 March 2018 and the published year to date reviewed figures upto the end of the 3rd Qtr ended 31 Dec 2017.

6) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date : 14 th Aug ' 2018



SUVEN LIFE SCIENCES LTD

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500 034, Telangana, India.

CIN: L24110TG1989PLC009713

Tel: 91 40 2354 1142/ 3311/ 3315 **Fax:** 91 40 2354 1152 **email:** investorservices@suvan.com **website:** www.suvan.com

EXTRACT OF STATEMENT OF STANDALONE UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 th JUNE,2018

SI No.	Particulars	Rs. In Lakhs		
		Quarter ending 30/06/2018 Un Audited	Year ending 31/03/2018 Audited	Quarter ending 30/06/2017 Un Audited
1	Total income from operations	19,166.22	62,525.84	14,101.90
2	Net profit /(loss) for the period (Before tax , exceptional and/or extraordinary items)	5,978.27	23,026.57	4,444.78
3	Net profit /(loss) for the period before tax (After exceptional and/or extraordinary items)	5,978.27	23,026.57	4,444.78
4	Net profit /(loss) for the period After tax (After exceptional and/or extraordinary items)	3,884.21	15,842.73	2,957.07
5	Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)	3,877.29	15,815.05	2,954.63
6	Equity share capital	1,272.82	1,272.82	1,272.82
7	Reserves (Excluding Revaluation Reserve) as shown in the audited balance sheet.		85,397.16	
8	Earnings Per Share (Of Rs.1.00/- each) (For continuing and discontinued operations) -			
	1. Basic :	3.05	12.43	2.32
	2. Diluted:	3.05	12.43	2.32
		(not annualised)		(not annualised)

Notes

1. The above is an extract of the detailed format of Quarterly/ Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the stock exchanges(s) and the listed entity. (www.bseindia.com and www.nseindia.com) and company's website www.suvan.com .

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI

Chairman & CEO

DIN: 00278028

Place : Hyderabad

Date: 14 th Aug, 2018